ERBB2 and breast cancer: Pyrotinib (SHR-1258), an oral irreversible pan-HER TKI, was first conditionally approved in China in 2018 in combination with capecitabine for the treatment of patients with HER2-positive advanced or metastatic BC (Xuhong et al., 2019).